HOME > BUSINESS

    BUSINESS

    Takeda’s £46 Billion Shire Buyout

    Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold

    Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

    TRENDS

    Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
    By Reiji Anasako

    While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

    COMMENTARY

    Does Dissolution of Japan Vaccine Signal Demise of Model in Vaccine Industry Vision, or Will a Second Round of JV Take Place?
    By Yoshinori Sagehashi

    Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

    COLUMN

    Expat Truths from the Japanese Medical Device World
    By Gregory Ng

    To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…